Elite in Stomach Cancer

Dr. Daniel V. Catenacci

Hematology | Oncology
5841 S Maryland Ave, 
Chicago, IL 
Accepting New Patients
Elite in Stomach Cancer
5841 S Maryland Ave, 
Chicago, IL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Daniel Catenacci is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Catenacci is rated as an Elite provider by MediFind in the treatment of Stomach Cancer. His top areas of expertise are Stomach Cancer, Cholangiocarcinoma (Bile Duct Cancer), Gastroesophageal Junction Cancer, and Colorectal Cancer. Dr. Catenacci is currently accepting new patients.

His clinical research consists of co-authoring 107 peer reviewed articles and participating in 23 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 51 articles and participated in 9 clinical trials in the study of Stomach Cancer.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in IL
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Oscar
  • EPO
  • HMO
  • PPO

Locations

5841 S Maryland Ave, Chicago, IL 60637

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

23 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: October 01, 2025
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
A Phase 1b/2 Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers
Enrollment Status: Active_not_recruiting
Publish Date: September 09, 2025
Intervention Type: Drug
Study Drugs: Tucatinib, Trastuzumab, Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine
Study Phase: Phase 2
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
COLOMATE: Colorectal Cancer Liquid Biopsy Screening Protocol for Molecularly Assigned Therapy
Enrollment Status: Terminated
Publish Date: August 29, 2025
Intervention Type: Other
A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer
Enrollment Status: Completed
Publish Date: March 17, 2025
Intervention Type: Biological
Study Drug: Margetuximab+Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
A Phase 1 Study of ZW49 in Patients With Locally Advanced (Unresectable) or Metastatic HER2-Expressing Cancers
Enrollment Status: Completed
Publish Date: January 29, 2025
Intervention Type: Drug
Study Drug: ZW49
Study Phase: Phase 1
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study
Impact of Early FDG-PET Directed Intervention on Preoperative Therapy for Locally Advanced Gastric Cancer: A Random Assignment Phase II Study
Enrollment Status: Terminated
Publish Date: January 20, 2025
Intervention Type: Drug, Radiation, Procedure
Study Phase: Phase 2
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
MOUNTAINEER: A Phase II, Open Label Study of Tucatinib Combined With Trastuzumab in Patients With HER2+ Metastatic Colorectal Cancer
Enrollment Status: Completed
Publish Date: November 26, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
A Randomized Phase II Study of Regorafenib Followed by Anti-EGFR Monoclonal Antibody Therapy Versus the Reverse Sequencing for Metastatic Colorectal Cancer Patients Previously Treated With Fluoropyrimidine, Oxaliplatin and Irinotecan (REVERCE II)
Enrollment Status: Active_not_recruiting
Publish Date: September 27, 2024
Intervention Type: Biological, Drug
Study Drugs: Cetuximab, Irinotecan, Panitumumab, Regorafenib
Study Phase: Phase 2
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
A Phase 2 Open-Label Clinical Trial of ADP-A2M4CD8 in Subjects With Advanced Esophageal or Esophagogastric Junction Cancers
Enrollment Status: Terminated
Publish Date: September 04, 2024
Intervention Type: Genetic
Study Phase: Phase 2
A Window of Opportunity Study of Pembrolizumab in Colon Cancer
A Window of Opportunity Study of Pembrolizumab in Colon Cancer
Enrollment Status: Withdrawn
Publish Date: July 31, 2024
Intervention Type: Procedure, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
A Phase 1 Open-Label, Dose-Finding Study Evaluating Safety and Pharmacokinetics of FPA144 in Patients With Advanced Solid Tumors
Enrollment Status: Completed
Publish Date: June 04, 2024
Intervention Type: Drug
Study Phase: Phase 1
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
PULSE: A Randomized, Phase II Open Label Study of PanitUmumab RechaLlenge Versus Standard Therapy After Progression on Anti-EGFR Therapy in Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2024
Intervention Type: Other, Biological, Drug
Study Drugs: Panitumumab, Regorafenib, Trifluridine, Tipiracil
Study Phase: Phase 2
A Phase II Trial of Neoadjuvant Pembrolizumab for Resectable Early Stage Gastroesophageal Adenocarcinoma
A Phase II Trial of Neoadjuvant Pembrolizumab for Resectable Early Stage Gastroesophageal Adenocarcinoma
Enrollment Status: Terminated
Publish Date: May 20, 2024
Intervention Type: Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients With Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
A Phase II, Multicenter, Single-Arm Study of Pemigatinib in Patients With Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Enrollment Status: Active_not_recruiting
Publish Date: February 21, 2024
Intervention Type: Other, Drug
Study Drug: Pemigatinib
Study Phase: Phase 2
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
A Phase 2 Study of Savolitinib in Subjects With MET Amplified Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: October 17, 2023
Intervention Type: Drug
Study Drug: Savolitinib
Study Phase: Phase 2
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Phase 1 Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer
Enrollment Status: Completed
Publish Date: August 29, 2023
Intervention Type: Drug, Biological
Study Phase: Phase 1/Phase 2
A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME)
A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME)
Enrollment Status: Unknown
Publish Date: February 01, 2023
Intervention Type: Drug
Study Drugs: Rucaparib, Ramucirumab, Nivolumab
Study Phase: Phase 1/Phase 2
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)
Enrollment Status: Completed
Publish Date: September 23, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
A Phase 1 Study to Evaluate the Safety, Proliferation and Persistence of GEN-011, an Autologous Adoptive Cell Therapy Targeting Neoantigens in Solid Tumors
Enrollment Status: Terminated
Publish Date: July 15, 2022
Intervention Type: Drug, Biological
Study Drugs: IL-2, Fludarabine, Cyclophosphamide
Study Phase: Phase 1
An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies
An Open-Label, Multicenter Phase 1a/2a Trial Investigating the Safety, Tolerability and Antitumor Activity of Multiple Doses of Sym015, a Monoclonal Antibody Mixture Targeting MET, in Patients With Advanced Solid Tumor Malignancies
Enrollment Status: Completed
Publish Date: June 22, 2022
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma
PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma
Enrollment Status: Completed
Publish Date: April 08, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas
A Phase 2, Open-label Evaluation of CRS-207 and Pembrolizumab in Adults With Recurrent or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinomas
Enrollment Status: Terminated
Publish Date: April 04, 2019
Intervention Type: Biological
Study Phase: Phase 2
View 22 Less Clinical Trials

107 Total Publications

An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202.
Journal: ESMO open
Published: January 31, 2024
Similar Doctors
Distinguished in Stomach Cancer
Dr. Mary F. Mulcahy
Hematology | Oncology
Distinguished in Stomach Cancer
Dr. Mary F. Mulcahy
Hematology | Oncology
675 N St Clair St Ste 21-100, Galter Pavilion, 
Chicago, IL 
 (7.4 miles away)
866-587-4322
Experience:
32+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Mary Mulcahy is a Hematologist and an Oncologist in Chicago, Illinois. Dr. Mulcahy has been practicing medicine for over 32 years and is rated as a Distinguished provider by MediFind in the treatment of Stomach Cancer. Her top areas of expertise are Colorectal Cancer, Pancreatic Cancer, Neuroendocrine Tumor, Liver Embolization, and Pancreaticoduodenectomy.

Kevin Dawravoo
Distinguished in Stomach Cancer
Dr. Kevin Dawravoo
Hematology | Oncology
Distinguished in Stomach Cancer
Dr. Kevin Dawravoo
Hematology | Oncology
4405 Weaver Pkwy, 
Waterman, IL 
 (29.8 miles away)
815-334-5566
Experience:
19+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Dawravoo is a Hematologist and an Oncologist in Waterman, Illinois. Dr. Dawravoo has been practicing medicine for over 19 years and is rated as a Distinguished provider by MediFind in the treatment of Stomach Cancer. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lynch Syndrome, and Gallbladder Adenocarcinoma.

Michael S. Schieber
Advanced in Stomach Cancer
Dr. Michael S. Schieber
Hematology | Oncology
Advanced in Stomach Cancer
Dr. Michael S. Schieber
Hematology | Oncology
2701 Patriot Blvd, 
Glenview, IL 
 (24.5 miles away)
630-924-4009
Experience:
10+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michael Schieber is a Hematologist and an Oncologist in Glenview, Illinois. Dr. Schieber has been practicing medicine for over 10 years and is rated as an Advanced provider by MediFind in the treatment of Stomach Cancer. His top areas of expertise are Stomach Cancer, Breast Cancer, Paget Disease of the Breast, and Schnitzler Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Catenacci's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile